Thyroid Disorders in Women with Breast Cancer
Authors: Hajtmanová E., Muríň P., Kinclová I., Hajtman A., Péč M., Kostková Ľ., Kočišová M.
Authors - sphere of activity: 1 Onkologické centrum, UN Martin, Slovenská republika, 2 Súdno-lekárske pracovisko Úradu pre dohľad nad zdravotnou starostlivosťou, pobočka Martin, Slovenská republika, 3 Ústav lekárskej biológie, JLF UK Martin, Slovenská republika
Article: Klin Onkol 2012; 25(2): 124-129
Category: Original Articles
Number of articles displayed: 121x
Increasing prevalence of non-malignant thyroid disorders in women with breast cancer has been known for several decades; it is said to be associated with a better prognosis of the cancerous disease.
The aim of this work was to analyse associations between thyropathies found in women with breast cancer and particular prognostic factors.
Patients and Methods:
A group of 110 women with breast cancer were tested for autoimmune thyroiditis (AIT) and functional changes of the thyroid gland. Presence of thyroid-peroxidase autoantibodies (TPOAb), serum levels of thyroid-stimulating hormone (TSH) and free thyroxine (FT3, FT4) were determined after the surgery but before adjuvant cancer treatment (radiotherapy, chemotherapy or hormone therapy) initiation. Conventionally evaluated prognostic factors of breast cancer, including histological grading and molecular predictive factors (i.e. the status of the hormone receptors and the human epidermal growth factor receptor) were assessed – these were divided into four basic categories.
Results and Conclusions:
The incidence of AIT and subclinical hypothyroidism in the study group was 37.3% and 20%, respectively, i.e. higher than in the general population. The only correlation found was between thyropathies and the specific prognostic factors was that with G1 breast cancer grading.
breast cancer – autoimmune thyroiditis – hypothyroidism – thyroid-stimulating hormone – free thyroxine – thyroid peroxidase – estrogen receptor – progesterone receptor – HER2 receptor
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.
4. 8. 2011
13. 10. 2011
The full wording of this article is available only to registered users. Plese register and you can read this article immediately.
If you are a subscriber, log in and enter the subscriber code from your magazine cover.
If you are not a subscriber, log in for unlimited access to older editions.
Tento článek si můžete přečíst pokud si aktivujete Premium účet.
- Cancer as a Metabolic Disease and Diabetes as a Cancer Risk? | views: 49
- The Role of Platelets in Tumour Growth | views: 24
- p63 – an Important Player in Epidermal and Tumour Development | views: 15
- PThe Regulation of p53 Synthesis | views: 12
- Detection of Cancer Stem Cell Markers in Sarcomas | views: 11
- Protein Quality Control and Cancerogenesis | views: 10
- RECAMO – ...through Cancer Research towards Applied Molecular Oncology; Where, Why and How | views: 7
- NKT-like Cells are Expanded in Solid Tumour Patients | views: 6
- The Many Roles of Molecular Chaperones and Co-chaperones in Tumour Biology | views: 6
- Circulating Levels of B-cell Activating Factor in Paediatric Patients with Malignancy With or without Cancer-Related Cachexia | views: 4